Overview

Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma

Status:
Unknown status

Trial end date:
2014-06-01

Target enrollment:
0

Participant gender:
All

Summary

Oncoxin in combination with Surafenib is safe and results in improved survival in patients with hepatocellular carcinoma (HCC)

Phase:

Phase 2/Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Clinical Research Organization, Dhaka, Bangladesh

Treatments:

Sorafenib

Criteria

Inclusion Criteria:

- Patients with HCC irrespective of etiology, age, gender and status of underlying liver
disease.

- Patients with HCC who are not suitable candidates for established modalities of
treatment i.e. surgery and/or chemotherapy.

- Patients with HCC who have evidence of tumor metastasis

- Patients with HCC who are voluntarily unwilling to take established modalities of
treatment i.e. surgery and/or chemotherapy.

- Patients with HCC in whom all possible treatment options have been exhausted.

Exclusion Criteria:

- Patients with HCC who are suitable candidates for established modalities of treatment
i.e. surgery and/or chemotherapy.

- Patients with HCC who have no evidence of tumor metastasis

- Patients with HCC who are willing to take established modalities of treatment i.e.
surgery and/or chemotherapy.

- Patients with HCC who are voluntarily unwilling to be included in the trial